ABIVAX (EPA:ABVX) | WebDisclosure

Basculer en Français

8201	Companies
109005	Keywords
51275	Articles
60079	Press releases

Home
Companies
ABIVAX

PRESS RELEASE

published on 10/07/2024 at 22:01, 26 days 15 hours ago

Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation
Abivax congratulates Victor Ambros and Gary Ruvkun on their Nobel Prize for the discovery of microRNA and its role in post-transcriptional gene regulation

Abivax MicroRNA Nobel Prize Victor Ambros Gary Ruvkun
PRESS RELEASE

published on 10/07/2024 at 22:01, 26 days 15 hours ago

Abivax félicite Victor Ambros et Gary Ruvkun pour leur prix Nobel, récompensant leur découverte du microARN et son rôle dans la régulation post transcriptionnelle des gènes
Abivax félicite Victor Ambros et Gary Ruvkun pour leur prix Nobel concernant la découverte du microARN et sa régulation post-transcriptionnelle des gènes. Réactions et objectifs d'Abivax pour l'avenir

Abivax Rectocolite Hémorragique MicroARN Prix Nobel Innovation Thérapeutique
BRIEF

published on 10/03/2024 at 22:06, 30 days 15 hours ago

Abivax recrute un premier patient pour son essai clinique sur la maladie de Crohn

Biotechnologie Abivax Obefazimod Maladie De Crohn Essai Clinique
BRIEF

published on 10/03/2024 at 22:06, 30 days 15 hours ago

Abivax recruits first patient for its clinical trial on Crohn's disease

Biotechnology Abivax Obefazimod Clinical Trial Crohn's Disease
PRESS RELEASE

published on 10/03/2024 at 22:01, 30 days 15 hours ago

Abivax annonce le recrutement d'un premier patient dans Enhance-CD, l'essai clinique de phase 2b avec obefazimod dans la maladie de Crohn
Abivax annonce le recrutement du premier patient dans Enhance-CD, l'essai clinique de phase 2b avec obefazimod dans la maladie de Crohn

Abivax Obefazimod Maladie De Crohn Phase 2b Essai Clinique
PRESS RELEASE

published on 10/03/2024 at 22:01, 30 days 15 hours ago

Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease
Abivax announces enrollment of first patient in Phase 2b trial of Obefazimod for Crohn's Disease, aiming for convenient, effective treatment option with fewer daily burdens

Abivax Obefazimod Phase 2B Trial Immune Response Crohn's Disease
PRESS RELEASE

published on 10/03/2024 at 22:01, 30 days 15 hours ago

Abivax annonce le recrutement d'un premier patient dans Enhance-CD, l'essai clinique de phase 2b avec obefazimod dans la maladie de Crohn
Abivax recrute premier patient pour Enhance-CD, essai clinique phase 2b obefazimod maladie Crohn. Etude 3 phases. Obefazimod, traitement prometteur

Abivax Obefazimod Maladie De Crohn Essai Clinique Enhance-CD
BRIEF

published on 10/03/2024 at 08:35, 1 month ago

Abivax Announces Positive Results for Obefazimod in Ulcerative Colitis Treatment

Abivax Obefazimod Ulcerative Colitis Clinical Study Safety Analysis
BRIEF

published on 10/03/2024 at 08:35, 1 month ago

Abivax annonce des résultats positifs pour l'obéfazimod dans le traitement de la rectocolite hémorragique

Abivax Obefazimod Rectocolite Hémorragique Étude Clinique Analyse De Sécurité
PRESS RELEASE

published on 10/03/2024 at 08:30, 1 month ago

Résultats positifs d'une analyse intermédiaire portant sur l'efficacité et la tolérance d’obefazimod 25 mg chez des patients atteints de RCH modérée à sévère après deux ans de maintenance en ouvert
Abivax annonce des résultats positifs pour obefazimod 25 mg chez les patients atteints de RCH modérée à sévère après 2 ans de maintenance. Analyse intermédiaire d'une étude de 6 ans

Abivax Obefazimod Efficacité RCH Rémission Clinique

Accesswire

Published on 11/03/2024 at 00:45, 12 hours 21 minutes ago

Holtway Global Hedge Expands into Europe, Providing Exclusive Pre-IPO and IPO Access to Companies Led by Visionary Founders like Elon Musk and Sam Altman
Published on 11/02/2024 at 19:15, 17 hours 51 minutes ago

Hank Payments Announces Closing of Financing and Settlements
Published on 11/02/2024 at 16:10, 20 hours 56 minutes ago

Savencia Cheese USA Announces Voluntary Recall of Select Soft Ripened Cheeses
Published on 11/02/2024 at 14:30, 22 hours 36 minutes ago

Spa Sciences Health Introduces Revolutionary Nasal Irrigation System at CVS
Published on 11/02/2024 at 00:48, 1 day 12 hours ago

OneSoft Solutions Inc. Announces the Completion of Its Acquisition by Irth Solutions LLC, a Blackstone Portfolio Company

View all ACCESSWIRE

EQS Group

Published on 11/01/2024 at 21:31, 1 day 15 hours ago

Original-Research: Telefonica Deutschland Holding AG (von First Berlin Equity Research GmbH): Buy
Published on 11/01/2024 at 18:18, 1 day 18 hours ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/01/2024 at 17:47, 1 day 19 hours ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/01/2024 at 17:10, 1 day 19 hours ago

EQS-Adhoc: fox e-mobility AG: provisional debt restructuring moratorium of Fox Automotive Switzerland AG
Published on 11/01/2024 at 16:00, 1 day 21 hours ago

Total Voting Rights

Les Echos

Published on 10/31/2024 at 20:26, 2 days 16 hours ago

I.CERAM - Résultat du 1er semestre 2024
Published on 10/31/2024 at 18:19, 2 days 18 hours ago

Déclaration hebdomadaire d'opérations effectuées du 28 au 31 octobre 2024
Published on 10/31/2024 at 18:19, 2 days 18 hours ago

Disclosure of transactions in own shares on October 28 to October 31, 2024
Published on 10/31/2024 at 18:00, 2 days 19 hours ago

GUILLEMOT CORPORATION : CHIFFRE D’AFFAIRES TROISIEME TRIMESTRE 2024 : +3%
Published on 10/31/2024 at 18:00, 2 days 19 hours ago

GUILLEMOT CORPORATION: THIRD QUARTER 2024 TURNOVER UP 3%

View all LES ECHOS COMFI WIRE